Organization
Asher Biotherapeutics
1 clinical trial
Clinical trial
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-01